Valneva SE announced the earnings guidance for 2024. For the year Product sales expected between ?150 million and ?180 million, reflecting continued revenue growth for proprietary products and IXCHIQ®?s launch-year sales, despite anticipated supply constraints for third-party products and IXIARO®.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.28 EUR | -5.53% |
|
-15.20% | -30.51% |
Jun. 04 | Pfizer: article on Lyme vaccine in The Lancet | CF |
Jun. 04 | Valneva: article on Lyme vaccine in The Lancet | CF |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.51% | 488M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva Se Announces Earnings Guidance for 2024